2029 Patients Physicians 
World of DTC Marketing
AUGUST 7, 2022
The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.
pharmaphorum
NOVEMBER 18, 2022
Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 10, 2023
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
Pharmaceutical Technology
FEBRUARY 3, 2023
Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 billion in 2022.
Pharmaceutical Technology
JUNE 22, 2008
Pharmaceutical companies dealing with the US will be closely watching the debate surrounding a proposed revision by the Senate which could see the watering down of some requirements, and an increase in others, under its Physician Payments Sunshine Act (S.2029). The benefits for the industry of adhering to the Act should not be overlooked.
PM360
APRIL 7, 2023
However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.
Clarivate
OCTOBER 17, 2024
The Inflation Reduction Act instead allows the Centers for Medicare & Medicaid Services to begin negotiating Fair Maximum Prices for a growing list of Part D (outpatient) and Part B (physician-administered) drugs that represent the greatest cost to the federal government. As of Aug.
Expert insights. Personalized for you.
263 
Let's personalize your content